Endo Says FDA Accepts Application For Nebido

Stock quotes in this article: ENDP , IDEV  

CHADDS FORD, Pa. (AP) — The Food and Drug Administration accepted Endo Pharmaceuticals Holdings Inc.'s application for the testosterone drug candidate Nebido, Endo said Thursday.

The FDA accepted a New Drug Application for Nebido and intends to rule on the drug by Sept. 2. The U.S. rights to the drug are held by Indevus Pharmaceuticals Inc., which was bought by Endo earlier this year.

Nebido is a long-lasting injection designed to treat hypogonadism, a hormonal condition that interferes with the functioning of the testes. The drug is already approved in Europe, where it is marketed by BayerSchering.

Endo shares slipped 13 cents to $16.52 in midday trading, and Indevus shares gained 6 cents to $5.77.

  • Loading Comments...
  •  

SHARE:

  • email
  • print
  • comment
  • digg
  • delicious
  • linkedin
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Recent Comments





Connect with TheStreet

Dow Jones S&P 500 NASDAQ 10-Year Note
10,441.12 1,109.18 2,206.91 35.96
Oil *
73.54
DOWN
10.88
UP
1.25
UP
5.86
DOWN
0.07
10 Yr
3.60%
SPDR Gold
111.59
-0.10%
+0.11%
+0.27%
-0.19%
Data delayed 20 minutes

More From TheStreet

Latest Headlines

Brokerage Partners

TheStreet Premium Services

All Services